FATE — Fate Therapeutics Share News
0.000.00%
Last trade - 00:00- $252.82m
- $110.94m
- $6.65m
Fate Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview
H.C. Wainwright bullish on Nkarta's lead cancer drug potential
Fate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Fate Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Highlights Operational Progress
Fate Therapeutics Inc expected to post a loss of 67 cents a share - Earnings Preview
Brief: Fate Therapeutics Highlights Positive Durability Of Response Data From FT516 Phase 1 Study For B-Cell Lymphoma
Fate Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Fate Therapeutics Reports Publication of FT538 Preclinical Data
Fate Therapeutics slumps over mixed data on cancer drugs
Brief: Fate Therapeutics Announces Positive Interim Clinical Data From FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
Fate Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Fate Therapeutics Posts Q2 Revenue Of $13.4 Mln
Brief: Fate Therapeutics Appoints Yuan Xu To Its Board
Fate Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Fate Therapeutics Announces Treatment Of First Patient In Landmark Phase 1 Clinical Trial Of FT819, The First-Ever IPSC-Derived Car T-Cell Therapy
Brief: Fate Therapeutics Appoints Mark Plavsic As Chief Technical Officer
Brief: Fate Therapeutics Highlights Positive Interim Data From Phase 1 Study Of Ft516 For B-Cell Lymphoma
Biotech deal activity to pick up pace after recent share pullback- Jefferies
Brief: Fate Therapeutics Announces Interim Phase 1 Data For iPSC-derived NK Cell Programs In Relapsed/Refractory Acute Myeloid Leukemia